Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Pharmacy | Rheumatology | Conference News

Back to Journal Articles

ACR: Early Damage Predicts Future Damage, Death in SLE

Last Updated: October 29, 2013.

 

Second study shows poor medication adherence among U.S. Medicaid beneficiaries with SLE

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with systemic lupus erythematosus (SLE), early damage predicts future damage and mortality; in addition, U.S. patients with SLE have poor medication adherence, according to two studies presented at the annual meeting of the American College of Rheumatology, held from Oct. 25 to 30 in San Diego.

TUESDAY, Oct. 29 (HealthDay News) -- For patients with systemic lupus erythematosus (SLE), early damage predicts future damage and mortality; in addition, U.S. patients with SLE have poor medication adherence, according to two studies presented at the annual meeting of the American College of Rheumatology, held from Oct. 25 to 30 in San Diego.

Ian N. Bruce, M.D., from the University of Manchester in the United Kingdom, and colleagues investigated damage accrual in early SLE using data from the Systemic Lupus International Collaborating Clinic (SLICC) Inception Cohort Study involving 1,722 patients from 31 centers in 11 countries. The researchers found that 34.8 percent of patients had one or more item of damage at baseline, increasing to 51.1 percent by six-year follow-up. For patients with initial damage, the SLICC/American College of Rheumatology damage index (SDI) was more likely to be increased at each follow-up visit. Each point increase in SDI correlated with a significantly increased risk of death (hazard ratio, 1.46).

Jinoos Yazdany, M.D., M.P.H., from the University of California in San Francisco, and colleagues examined medication adherence in SLE patients using U.S. Medicaid Analytic eXtract data from 2000 to 2006. The researchers found that the medication possession ratios (MPRs) varied from 31.1 percent for tacrolimus to 56.9 percent for hydroxychloroquine. Blacks had lower adherence than whites across all medications. Few patients had MPRs of ≥80 percent (14 percent for tacrolimus and 40 percent for mycophenolate mofetil).

"This study tells us that working with lupus patients to improve adherence is central to improving health outcomes," Yazdany said in a statement.

Abstract - Bruce
Abstract - Yazdany
More Information

Copyright © 2013 HealthDay. All rights reserved.


Previous: AAP: Helmet Brand Doesn't Impact Sport-Tied Concussion Next: Docs, Lawyers Join Forces to Allow Doctors to Apologize

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.